Free Trial

Amarin (AMRN) Competitors

Amarin logo
$10.99 +0.01 (+0.09%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$10.75 -0.24 (-2.18%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AMRN vs. ARDX, ZYME, LENZ, CVAC, CRMD, CMRX, CDMO, CRON, PRAX, and NRIX

Should you be buying Amarin stock or one of its competitors? The main competitors of Amarin include Ardelyx (ARDX), Zymeworks (ZYME), LENZ Therapeutics (LENZ), CureVac (CVAC), CorMedix (CRMD), Chimerix (CMRX), Avid Bioservices (CDMO), Cronos Group (CRON), Praxis Precision Medicines (PRAX), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry.

Amarin vs.

Amarin (NASDAQ:AMRN) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk.

In the previous week, Ardelyx had 17 more articles in the media than Amarin. MarketBeat recorded 18 mentions for Ardelyx and 1 mentions for Amarin. Ardelyx's average media sentiment score of 0.90 beat Amarin's score of 0.75 indicating that Ardelyx is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Amarin
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ardelyx
6 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Amarin received 305 more outperform votes than Ardelyx when rated by MarketBeat users. Likewise, 73.20% of users gave Amarin an outperform vote while only 67.46% of users gave Ardelyx an outperform vote.

CompanyUnderperformOutperform
AmarinOutperform Votes
844
73.20%
Underperform Votes
309
26.80%
ArdelyxOutperform Votes
539
67.46%
Underperform Votes
260
32.54%

Amarin has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Ardelyx has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500.

Ardelyx has higher revenue and earnings than Amarin. Ardelyx is trading at a lower price-to-earnings ratio than Amarin, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amarin$214.11M1.06-$59.11M-$3.64-3.02
Ardelyx$361.71M2.62-$39.14M-$0.22-18.00

22.3% of Amarin shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 3.3% of Amarin shares are held by insiders. Comparatively, 4.8% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ardelyx has a net margin of -11.73% compared to Amarin's net margin of -16.33%. Amarin's return on equity of -7.22% beat Ardelyx's return on equity.

Company Net Margins Return on Equity Return on Assets
Amarin-16.33% -7.22% -4.96%
Ardelyx -11.73%-24.87%-10.51%

Amarin presently has a consensus price target of $7.00, suggesting a potential downside of 36.31%. Ardelyx has a consensus price target of $10.39, suggesting a potential upside of 162.35%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts clearly believe Ardelyx is more favorable than Amarin.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amarin
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Ardelyx
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.90

Summary

Ardelyx beats Amarin on 15 of the 19 factors compared between the two stocks.

Get Amarin News Delivered to You Automatically

Sign up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AMRN vs. The Competition

MetricAmarinPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$227.59M$6.47B$5.33B$8.39B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-122.119.0626.7919.70
Price / Sales1.06259.83393.69121.79
Price / CashN/A65.8538.2534.62
Price / Book8.146.456.774.50
Net Income-$59.11M$143.98M$3.23B$248.22M
7 Day Performance3.88%0.38%0.42%-0.80%
1 Month Performance6.08%2.14%9.06%11.52%
1 Year Performance-34.92%-0.33%18.55%8.99%

Amarin Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AMRN
Amarin
0.3588 of 5 stars
$10.99
+0.1%
$7.00
-36.3%
-37.0%$227.59M$214.11M-122.11360
ARDX
Ardelyx
4.4936 of 5 stars
$3.53
-2.5%
$10.39
+194.3%
-49.4%$844.57M$361.71M-22.0690Insider Trade
Gap Down
ZYME
Zymeworks
3.3609 of 5 stars
$12.02
+6.3%
$21.00
+74.7%
+27.3%$836.32M$76.30M-8.01460News Coverage
Positive News
Analyst Forecast
Analyst Revision
LENZ
LENZ Therapeutics
1.9263 of 5 stars
$29.37
+11.5%
$46.60
+58.7%
+53.3%$826.65MN/A-16.59110Gap Up
CVAC
CureVac
3.5763 of 5 stars
$3.62
+4.3%
$14.00
+286.7%
+6.4%$812.10M$535.18M6.58880News Coverage
Earnings Report
CRMD
CorMedix
2.0819 of 5 stars
$11.86
+1.7%
$15.00
+26.5%
+135.3%$804.40M$82.55M-14.6430
CMRX
Chimerix
0.5666 of 5 stars
$8.54
flat
$8.53
-0.1%
N/A$801.09M$212,000.00-9.0990
CDMO
Avid Bioservices
0.8011 of 5 stars
$12.50
+0.1%
$12.25
-2.0%
+37.5%$799.18M$139.91M-5.23320High Trading Volume
CRON
Cronos Group
1.0011 of 5 stars
$2.05
+3.5%
$3.50
+70.7%
-26.5%$790.08M$117.62M-15.77450Positive News
High Trading Volume
PRAX
Praxis Precision Medicines
3.1548 of 5 stars
$38.42
+0.2%
$116.50
+203.2%
-10.0%$782.58M$8.12M-3.73110Positive News
NRIX
Nurix Therapeutics
2.3926 of 5 stars
$10.18
+7.2%
$30.44
+199.1%
-38.0%$776.08M$56.42M-3.52300Positive News
Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:AMRN) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners